A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
|Articles|May 15, 2012
FDA Concludes Safety Review Of Novartis MS Drug Gilenya
Advertisement
The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple- sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.
The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.
Read the full story:
Source: Morningstar
Advertisement
Related to this article
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
Advertisement
Advertisement
Trending on AJMC
1
Extension Studies in TPIP Show Promise in PAH, PH-ILD
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5